Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
Completed
Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2010
Locations: University of Maryland Medical Center Greenbaum Cancer Ctr, Baltimore, Maryland +1 locations
Conditions: Multiple Myeloma
Reduced Dexamethasone Pre-Medication Dose in Elderly Patients Receiving Weekly Docetaxel
Terminated
This study is to explore the feasibility of an alternative dose of dexamethasone pre-medication in older breast and lung cancer patients who are receiving weekly docetaxel chemotherapy.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
11/15/2007
Locations: Not set, Baltimore, Maryland
Conditions: Breast Cancer, Lung Cancer